Takeda Pharmaceutical Co. agreed to buy closely held Nycomed for €9.6 billion (¥1.12 trillion), the largest takeover by a Japanese drugmaker, broadening its reach in emerging markets and adding a remedy for smokers' cough to its portfolio.
Asia's largest pharmaceutical company will pay cash for Zurich-based Nycomed, which is controlled by Nordic Capital and Credit Suisse Group AG's private equity unit, Osaka-based Takeda said in a statement Thursday. The purchase price includes €3.6 billion of net debt.
Nycomed, which gets more than a third of its revenue from emerging markets, will reduce Takeda's reliance on sales in Japan and the United States.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.